caracemide

01/01/1999 - "A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer."
04/01/1987 - "We conducted a phase I trial of caracemide, a new chemotherapeutic agent, which is active in the MX1 (mammary) and CX1 (colon) human tumor xenografts. "
10/01/1984 - "Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from rat Novikoff tumor. "
10/01/1987 - "We compared the in vitro growth inhibition of primary human tumor cells in the adhesive tumor cell culture system (ATCCS), exposed to the investigational agents caracemide, spirogermanium and taxol and to standard chemotherapy agents at equitoxic concentrations for granulocyte-macrophage colony-forming cells (GM-CFC) in vitro. "
01/01/1988 - "These data indicate the value of human tumor cells to predict drug responsiveness and suggest the further evaluation of caracemide and its combination with hydroxyurea and iron-chelating agents in the treatment of human leukemias."

01/01/1996 - "A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer."
01/01/1996 - "Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). "

11/01/1987 - "Phase II study of caracemide in advanced or recurrent non-small cell lung cancer."

04/01/1992 - "Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. "

01/01/1999 - "Caracemide was well tolerated with the exception of one death due to sepsis. "